11 Best Nanotechnology Stocks To Invest In

In This Article:

In this piece, we will take a look at the 11 best nanotechnology stocks to invest in. If you want to skip our introduction to the nanotechnology sector and how it covers a variety of applications ranging from healthcare to consumer technology, then you can skip ahead to read 5 Best Nanotechnology Stocks To Invest In.

Just like artificial intelligence, nanotechnology is another set of technologies that once belonged to the realm of science fiction. Nanotechnology refers to items that are smaller than 100 nanometers. These are used in a wide variety of applications, such as sunscreen and medicines since the small size of the particles allows them to behave in ways that regularly sized items cannot.

One of the most lucrative applications of nanotechnology comes in the semiconductor industry. Modern day chips, such as those that power Apple Inc. (NASDAQ:AAPL)'s iPhone or the latest artificial intelligence graphics processing units from NVIDIA Corporation (NASDAQ:NVDA), are made of transistors that are often as small as just a couple of nanometers. In fact, the world's leading contract semiconductor manufacturer, the Taiwan Semiconductor Manufacturing Company (NYSE:TSM) is currently mass producing semiconductors with feature sizes as small as 3 nanometers. Nothing short of magic, making transistors that are just nanometers wide or long provides chips with dozens of benefits over their predecessors, with the most evident ones being improved electrical conductivity, better power efficiency, and of course, higher computing power.

Another well known user of nanotechnology is the medical industry. It is used for a wide variety of direct and indirect medicinal purposes, such as treating cancer, imaging diseases, and even making new tissues. One such company is the Paris, France based biotechnology firm Nanobiotix S.A. (NASDAQ:NBTX). A specialized biotechnology firm, Nanobiotix uses nano particles to fight cancers of the head, pancreas, and other regions and organs of the human body. The three analysts that cover the stock have rated the shares as Strong Buy on average, and priced in a hefty upside through an average share price target of $11.98. In fact, April 2024 is turning out to be a crucial month for Nanobiotix S.A. (NASDAQ:NBTX) as the firm completed the dose escalation portion of its first phase trial of a lung cancer treatment called NBTXR3.

The treatment targets small cell lung cancer, and it is aimed to help specifically those patients who cannot be treated by surgery or those who have seen their cancer return after earlier bouts of radiation therapy. It uses hafnium oxide nano particles, and Nanobiotix S.A. (NASDAQ:NBTX) is optimistic that while the current trial is only working with lung cancer patients, future uses of NBTXR3 could apply to other cancers as well given hafnium oxide's mechanism of action. Wall Street, it seems, is having a hard time believing the firm, as the stock is down by 15% year to date.